[Endothelin system and heart failure: a potential therapeutic target].
Neurohormonal activation is a marker and one of the most important pathophysiologic aspects of heart failure. The hyperactivation and participation of the endothelin system in several manifestations of this syndrome have been widely documented in the last few years. These data support attempts to view the endothelin system as a potential pharmacological target in order to reduce the high morbidity and mortality associated with heart failure. This is a short review of the main aspects of endothelin biology, its mechanisms of action, including those at the molecular level, and its pathophysiological role in heart failure. Finally, the potential benefits of the pharmacological manipulation of the endothelin system as well as some results of clinical trials in this context will be presented.